Medical Billing & Credentialing Services | Prohealthcare Advisors
Oncology billing carries some of the highest financial stakes in medicine — chemotherapy administration codes (96401–96549), biosimilar substitution rules, and prior authorization for high-cost specialty drugs each require precise, payer-specific handling. A single denied prior auth on a six-figure treatment plan can devastate a practice's cash flow. We track these details so oncology practices don't absorb that risk.
We manage license renewal tracking, monthly OIG/SAM exclusion checks, and enrollment across the payers and specialty pharmacy networks most active in oncology — so your team can focus on cancer care while we protect every claim, from chemotherapy administration to radiation therapy bundling.
Oncology Billing
Oncology Billing Complexity Areas
| Billing Area | Common Risk | How We Manage It |
|---|---|---|
| Chemo Administration (96401–96549) | Incorrect sequencing when multiple drugs are administered same-session | Session-level coding review before submission |
| Biosimilar Substitution | Payer-specific rules on originator vs. biosimilar billing | Payer-by-payer biosimilar policy tracking |
| High-Cost Drug Prior Auth | Denials on six-figure treatment plans | Pre-treatment authorization verification |
| ICD-10 Staging Specificity | Denials from insufficient staging detail | Documentation review against payer specificity requirements |
| Radiation Therapy Bundling | NCCI edits on same-course treatment codes | Modifier verification before claim submission |
Chemotherapy Billing Codes
Oncology claims are paid on a small set of elements — chemotherapy administration codes, biosimilar substitution rules, prior authorization for high-cost specialty drugs, staging specificity, and radiation therapy bundling. We check each one before a claim is submitted:
| Code(s) | Service | What We Check |
|---|---|---|
| 96401–96549 | Chemotherapy administration | Session-level coding review before submission — we check sequencing when multiple drugs are administered in the same session, the most common cause of denials under these codes. |
Payer Enrollment & Compliance
We manage license renewal tracking, monthly OIG/SAM exclusion checks, and enrollment across the payers and specialty pharmacy networks most active in oncology. Because high-cost drug authorizations often require re-verification mid-treatment, we monitor authorization status throughout a patient's full treatment course, not just at intake.
Staying enrolled keeps your practice paid: license renewal tracking and monthly OIG/SAM exclusion checks keep your credentials current, and enrollment across the payers and specialty pharmacy networks most active in oncology means authorizations and claims are not interrupted by a lapsed renewal or an enrollment gap.
Payers we enroll with include:
Chemotherapy administration is where oncology claims most often go wrong. When multiple drugs are administered in the same session, incorrect sequencing under codes 96401–96549 is the most common cause of denials — and a single denied prior authorization on a six-figure treatment plan can devastate a practice's cash flow. We review session-level coding before submission, so sequencing errors are caught before they reach the payer, not after a denial.
Enrollment is the first line of defense for oncology revenue. We manage license renewal tracking, monthly OIG/SAM exclusion checks, and enrollment across the payers and specialty pharmacy networks most active in oncology — so your practice stays enrolled and compliant, and authorizations and claims are not interrupted by a lapsed renewal or an enrollment gap.
Because high-cost drug authorizations often require re-verification mid-treatment, we monitor authorization status throughout a patient's full treatment course, not just at intake.
Oncology billing requires precise, payer-specific handling — biosimilar substitution rules, prior authorization for high-cost specialty drugs, and staging specificity all vary by payer. Using the wrong biosimilar, or submitting staging documentation that is not specific enough, can trigger denials.
We track payer-specific biosimilar policies and review documentation against each payer's specificity requirements before submission, so compliance is built into every claim.
A single denied prior authorization on a six-figure treatment plan can devastate a practice's cash flow. We track these details so oncology practices don't absorb that risk — verifying authorization before treatment begins and monitoring status throughout the full treatment course.
Every claim is checked before submission: session-level coding, biosimilar policy, staging specificity, and radiation bundling — so denials are prevented, not chased.
Common Questions
We verify authorization before treatment begins and monitor status throughout the full treatment course, since many high-cost drug authorizations require re-verification mid-treatment — a common point where practices lose revenue if not tracked proactively.
Yes — payers have different rules on originator versus biosimilar billing, and using the wrong one can trigger denials. We track payer-specific biosimilar policies to ensure correct billing.
The most common cause is incorrect sequencing when multiple drugs are administered in the same session under codes 96401–96549. We review session-level coding before submission to catch this.
Payers increasingly require detailed staging specificity to approve oncology claims. We review documentation against each payer's specificity requirements before submission to prevent denials.
Explore More
Locations
Free Payer Performance Audit — no sales pitch, benchmarked against oncology billing standards.
Request Your Free Audit →Call us today for comprehensive practice support. We specialize in billing, resolving claim denials, authorizations, patient statements, RCM reporting, credentialing, collections, and offering a wide range of services to expand and enhance your practice.
Opening Hours
Mon–Fri: 8am – 6pm
Sat: Closed
Sun: Closed
Contact Us
(888) 341-4599